Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model
- PMID: 23565251
- PMCID: PMC3614971
- DOI: 10.1371/journal.pone.0060463
Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model
Abstract
Linezolid (L), a potent antibiotic for Methicillin Resistant Staphylococcus aureus (MRSA), inhibits bacterial protein synthesis. By contrast, vancomycin (V) is a cell wall active agent. Here, we used a murine sepsis model to test the hypothesis that L treatment is associated with differences in bacterial and host characteristics as compared to V. Mice were injected with S. aureus USA300, and then intravenously treated with 25 mg/kg of either L or V at 2 hours post infection (hpi). In vivo alpha-hemolysin production was reduced in both L and V-treated mice compared to untreated mice but the reduction did not reach the statistical significance [P = 0.12 for L; P = 0.70 for V). PVL was significantly reduced in L-treated mice compared to untreated mice (P = 0.02). However the reduction of in vivo PVL did not reach the statistical significance in V- treated mice compared to untreated mice (P = 0.27). Both antibiotics significantly reduced IL-1β production [P = 0.001 for L; P = 0.006 for V]. IL-6 was significantly reduced with L but not V antibiotic treatment [P<0.001 for L; P = 0.11 for V]. Neither treatment significantly reduced production of TNF-α. Whole-blood gene expression profiling showed no significant effect of L and V on uninfected mice. In S. aureus-infected mice, L altered the expression of a greater number of genes than V (95 vs. 42; P = 0.001). Pathway analysis for the differentially expressed genes identified toll-like receptor signaling pathway to be common to each S. aureus-infected comparison. Expression of immunomodulatory genes like Cxcl9, Cxcl10, Il1r2, Cd14 and Nfkbia was different among the treatment groups. Glycerolipid metabolism pathway was uniquely associated with L treatment in S. aureus infection. This study demonstrates that, as compared to V, treatment with L is associated with reduced levels of toxin production, differences in host inflammatory response, and distinct host gene expression characteristics in MRSA sepsis.
Conflict of interest statement
Figures





Similar articles
-
Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia.J Infect Dis. 2013 Jul;208(1):75-82. doi: 10.1093/infdis/jit129. Epub 2013 Mar 26. J Infect Dis. 2013. PMID: 23532096 Free PMC article.
-
Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfection.PLoS One. 2013;8(3):e57483. doi: 10.1371/journal.pone.0057483. Epub 2013 Mar 5. PLoS One. 2013. PMID: 23478252 Free PMC article.
-
Methicillin-resistant Staphylococcus aureus-induced thrombo-inflammatory response is reduced with timely antibiotic administration.Thromb Haemost. 2013 Apr;109(4):684-95. doi: 10.1160/TH12-08-0543. Epub 2013 Jan 24. Thromb Haemost. 2013. PMID: 23348831 Free PMC article.
-
Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.Eur J Med Res. 2010 Nov 30;15(12):507-13. doi: 10.1186/2047-783x-15-12-507. Eur J Med Res. 2010. PMID: 21163725 Free PMC article. Review.
-
The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.Curr Med Res Opin. 2010 Mar;26(3):571-88. doi: 10.1185/03007990903512057. Curr Med Res Opin. 2010. PMID: 20055750 Review.
Cited by
-
Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent.Sci Rep. 2015 Nov 10;5:16407. doi: 10.1038/srep16407. Sci Rep. 2015. PMID: 26553420 Free PMC article.
-
Screening of Key Genes of Sepsis and Septic Shock Using Bioinformatics Analysis.J Inflamm Res. 2021 Mar 11;14:829-841. doi: 10.2147/JIR.S301663. eCollection 2021. J Inflamm Res. 2021. PMID: 33737824 Free PMC article.
-
Immunomodulatory effect of linezolid on methicillin-resistant Staphylococcus aureus supernatant-induced MUC5AC overexpression in human airway epithelial cells.Antimicrob Agents Chemother. 2014 Jul;58(7):4131-7. doi: 10.1128/AAC.02811-13. Epub 2014 May 12. Antimicrob Agents Chemother. 2014. PMID: 24820080 Free PMC article.
-
Systematic analysis of lysine crotonylation in human macrophages responding to MRSA infection.Front Cell Infect Microbiol. 2023 Feb 8;13:1126350. doi: 10.3389/fcimb.2023.1126350. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 36844408 Free PMC article.
-
Subinhibitory concentrations of tedizolid potently inhibit extracellular toxin production by methicillin-sensitive and methicillin-resistant Staphylococcus aureus.J Med Microbiol. 2019 Feb;68(2):255-262. doi: 10.1099/jmm.0.000905. Epub 2018 Dec 17. J Med Microbiol. 2019. PMID: 30556803 Free PMC article.
References
-
- Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339: 520–532. - PubMed
-
- Gould IM, David MZ, Esposito S, Garau J, Lina G, et al. (2012) New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 39: 96–104. - PubMed
-
- Kobayashi SD, DeLeo FR (2009) An update on community-associated MRSA virulence. Curr Opin Pharmacol 9: 545–551. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials